PMID- 35242198
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220502
IS  - 1741-427X (Print)
IS  - 1741-4288 (Electronic)
IS  - 1741-427X (Linking)
VI  - 2022
DP  - 2022
TI  - Yunnan Baiyao Adjuvant Treatment for Patients with Hemoptysis: A Systematic 
      Review and Meta-Analysis.
PG  - 4931284
LID - 10.1155/2022/4931284 [doi]
LID - 4931284
AB  - BACKGROUND: Yunnan Baiyao (YNBY) is a traditional Chinese medicine used to treat 
      bleeding. We evaluated the efficacy of YNBY plus conventional pharmaceutical 
      treatment (CPT) versus CPT alone in patients with hemoptysis. METHODS: A total of 
      eight electronic databases were searched. The outcomes in the included studies 
      were effective rate, hemoptysis volume, duration of hemoptysis and 
      hospitalization, number of cases requiring endotracheal intubation, and adverse 
      events (AEs). The studies were used to calculate risk ratios (RRs) or mean 
      differences (MDs) with corresponding 95% confidence intervals. Risk of bias for 
      included trials was assessed using the Cochrane risk of bias tool. RESULTS: 
      Thirteen RCTs were analyzed consisting of a total of 1379 patients. Treatment 
      with YNBY + CPT had a greater effective rate than CPT alone (RR: 1.18; 95% CI: 
      1.13 to 1.23; P < 0.001; I (2) = 0%), a lower hemoptysis volume (MD: -107.37; 95% 
      CI: -121.69 to -93.06; P < 0.001; I (2) = 0%), a shorter duration of hemoptysis 
      (MD: -2.70; 95% CI: -2.96 to 2.43; P < 0.001; I (2) = 0%) and hospitalization 
      (MD: -2.38; 95% CI: -2.93 to -1.83; P < 0.001; I (2) = 9%), and a reduction in 
      the incidence of AEs (RR: 0.34; 95% CI: 0.23 to 0.51; P < 0.001; I (2) = 0%). 
      YNBY + CPT treatment provided no significant difference in reducing the number of 
      cases requiring endotracheal intubation compared to CPT alone (RR: 0.49; 95% CI: 
      0.15 to 1.60; P=0.24; I (2) = 0%). CONCLUSION: YNBY plus CPT showed better 
      efficacy than CPT for patients with hemoptysis. Our study provides medical 
      evidence for the efficacy and safety of YNBY for hemoptysis.
CI  - Copyright (c) 2022 Yilan Wang et al.
FAU - Wang, Yilan
AU  - Wang Y
AUID- ORCID: 0000-0002-8230-4176
AD  - Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu 610072, 
      Sichuan Province, China.
FAU - Wang, Xiaomin
AU  - Wang X
AD  - Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu 610072, 
      Sichuan Province, China.
FAU - Fu, Hongfang
AU  - Fu H
AUID- ORCID: 0000-0002-2112-7401
AD  - Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu 610072, 
      Sichuan Province, China.
FAU - Kou, Shuo
AU  - Kou S
AD  - Zhejiang University of Traditional Chinese Medicine, Hangzhou 310053, Zhejiang 
      Province, China.
FAU - Huang, Demei
AU  - Huang D
AD  - Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu 610072, 
      Sichuan Province, China.
FAU - Shen, Zherui
AU  - Shen Z
AD  - Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu 610072, 
      Sichuan Province, China.
FAU - Wang, Fei
AU  - Wang F
AUID- ORCID: 0000-0002-8158-0742
AD  - Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu 610072, 
      Sichuan Province, China.
FAU - Wang, Zhenxing
AU  - Wang Z
AUID- ORCID: 0000-0001-6832-9652
AD  - Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu 610072, 
      Sichuan Province, China.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20220222
PL  - United States
TA  - Evid Based Complement Alternat Med
JT  - Evidence-based complementary and alternative medicine : eCAM
JID - 101215021
PMC - PMC8888054
COIS- The authors declare that they have no conflicts of interest.
EDAT- 2022/03/05 06:00
MHDA- 2022/03/05 06:01
PMCR- 2022/02/22
CRDT- 2022/03/04 05:40
PHST- 2021/07/20 00:00 [received]
PHST- 2022/01/20 00:00 [accepted]
PHST- 2022/03/04 05:40 [entrez]
PHST- 2022/03/05 06:00 [pubmed]
PHST- 2022/03/05 06:01 [medline]
PHST- 2022/02/22 00:00 [pmc-release]
AID - 10.1155/2022/4931284 [doi]
PST - epublish
SO  - Evid Based Complement Alternat Med. 2022 Feb 22;2022:4931284. doi: 
      10.1155/2022/4931284. eCollection 2022.